Suscripción a Biblioteca: Guest
Critical Reviews™ in Eukaryotic Gene Expression

Publicado 6 números por año

ISSN Imprimir: 1045-4403

ISSN En Línea: 2162-6502

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.6 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.2 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00058 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.33 SJR: 0.345 SNIP: 0.46 CiteScore™:: 2.5 H-Index: 67

Indexed in

Prostaglandin E—A Powerful Anabolic Agent for Generalized or Site-Specific Bone Formation

Volumen 13, Edición 2-4, 2003, 10 pages
DOI: 10.1615/CritRevEukaryotGeneExpr.v13.i24.170
Get accessGet access

SINOPSIS

Prostaglandins are locally secreted, rapidly metabolized, biologically active fatty acids first identified in the prostate. The role of prostaglandins in the inflammatory response has been widely studied. However, some prostaglandins, particularly those of the E series (PGEs), can suppress inflammation, making it difficult to understand the local events and their sequence. This bimodal potential of the PGEs has been poorly understood in skeletal biology, causing the initial report of PGEs as mediators of bone resorption to persist for more than two decades, despite ample evidence to the contrary. This resulted in part from the power of any initial report to overrule subsequent conflicting views and in part on the exclusive reliance on in vitro data to explain in vivo phenomena. Over a decade ago, the potential of PGEs as authentic anabolic skeletal agents was demonstrated convincingly in vivo by both systemic and local delivery. The potential clinical applications of the PGEs in skeletal biology have not yet been developed. Our purpose is to review the reasons for the delayed discovery of the true skeletal effects of the PGEs and to describe applications for this technology. With the development of appropriate delivery systems, one can anticipate widespread clinical applications of the PGEs to accelerate skeletal repair, and to treat skeletal pathologies and trauma.

CITADO POR
  1. Bodine Peter V.N., Billiard Julia, Moran Robert A., Ponce-de-Leon Helga, McLarney Sean, Mangine Annamarie, Scrimo Melissa J., Bhat Ramesh A., Stauffer Barbara, Green Jack, Stein Gary S., Lian Jane B., Komm Barry S., The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis, Journal of Cellular Biochemistry, 96, 6, 2005. Crossref

  2. Bradley J. D., Cleverly D. G., Burns A. M., Helm N. B., Schmid M. J., Marx D. B., Cullen D. M., Reinhardt R. A., Cyclooxygenase-2 inhibitor reduces simvastatin-induced bone morphogenetic protein-2 and bone formation in vivo, Journal of Periodontal Research, 42, 3, 2007. Crossref

  3. Atik O Sahap, Uslu M Murad, Eksioglu Fatih, Satana Tolgay, Etiology of Senile Osteoporosis, Clinical Orthopaedics & Related Research, 443, 2006. Crossref

  4. Preston Rhonda D., Meinberg Trudy A., Payne Jeffrey B., Schmid Marian J., Lee Hsi-Ming, Golub Lorne M., Marx David B., Reinhardt Richard A., Inflammatory mediator release following bone grafting in humans: a pilot study, Journal of Clinical Periodontology, 34, 9, 2007. Crossref

  5. Liu Xin-Ming, Wiswall Andrew T., Rutledge John E., Akhter Mohammed P., Cullen Diane M., Reinhardt Richard A., Wang Dong, Osteotropic β-cyclodextrin for local bone regeneration, Biomaterials, 29, 11, 2008. Crossref

  6. Choi Mi Ran, Das Nando Dulal, Jung Kyoung Hwa, Kim Seung Hyun, Kim Hyun Young, Kim Kyung Suk, Chai Young Gyu, Gene expression during long-term culture of mesenchymal stem cells obtained from patients with amyotrophic lateral sclerosis, BioChip Journal, 6, 4, 2012. Crossref

  7. Pan Huaizhong, Sima Monika, Miller Scott C., Kopečková Pavla, Yang Jiyuan, Kopeček Jindřich, Efficiency of high molecular weight backbone degradable HPMA copolymer–Prostaglandin E1 conjugate in promotion of bone formation in ovariectomized rats, Biomaterials, 34, 27, 2013. Crossref

  8. Pan Huaizhong, Kopečková Pavla, Wang Dong, Yang Jiyuan, Miller Scott, Kopeček JindŘich, Water-soluble HPMA copolymer—prostaglandin E1conjugates containing a cathepsin K sensitive spacer, Journal of Drug Targeting, 14, 6, 2006. Crossref

  9. Miller S. C., Pan H., Wang D., Bowman B. M., Kopečková P., Kopeček J., Feasibility of Using a Bone-Targeted, Macromolecular Delivery System Coupled with Prostaglandin E1 to Promote Bone Formation in Aged, Estrogen-Deficient Rats, Pharmaceutical Research, 25, 12, 2008. Crossref

  10. Ripoll Vera M., Irvine Katharine M., Ravasi Timothy, Sweet Matthew J., Hume David A., GpnmbIs Induced in Macrophages by IFN-γ and Lipopolysaccharide and Acts as a Feedback Regulator of Proinflammatory Responses, The Journal of Immunology, 178, 10, 2007. Crossref

  11. Pahl Madeleine V., Vaziri Nosratola D., Yuan Jun, Adler Sharon G., Upregulation of Monocyte/Macrophage HGFIN (Gpnmb/Osteoactivin) Expression in End-Stage Renal Disease, Clinical Journal of the American Society of Nephrology, 5, 1, 2010. Crossref

  12. Janssens Katrien, ten Dijke Peter, Janssens Sophie, Van Hul Wim, Transforming Growth Factor-β1 to the Bone, Endocrine Reviews, 26, 6, 2005. Crossref

  13. Itani Oussama, Tsang Reginald, Normal bone and mineral physiology and metabolism, in Neonatal Nutrition and Metabolism, 2006. Crossref

  14. Krischak G. D., Augat P., Blakytny R., Claes L., Kinzl L., Beck A., The non-steroidal anti-inflammatory drug diclofenac reduces appearance of osteoblasts in bone defect healing in rats, Archives of Orthopaedic and Trauma Surgery, 127, 6, 2007. Crossref

  15. Kobayashi Yasuhiro, Take Ikuko, Yamashita Teruhito, Mizoguchi Toshihide, Ninomiya Tadashi, Hattori Toshimi, Kurihara Saburo, Ozawa Hidehiro, Udagawa Nobuyuki, Takahashi Naoyuki, Prostaglandin E2 Receptors EP2 and EP4 Are Down-regulated during Differentiation of Mouse Osteoclasts from Their Precursors, Journal of Biological Chemistry, 280, 25, 2005. Crossref

Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain